Literature DB >> 20955208

Assessment of serum sodium to urinary sodium divided by (serum potassium)² to urinary potassium as a screening tool for primary aldosteronism.

Olivier Steichen1, Anne Blanchard, Pierre-François Plouin.   

Abstract

BACKGROUND: The SUSPPUP ratio [(serum sodium/urinary sodium)/(serum potassium²/urinary potassium)] has been proposed as a marker to screen for primary aldosteronism (PA). The original study found an area under the receiver operating characteristic (ROC) curve of 0·90 to detect PA; the sensitivity was 89% and specificity 86% for a ratio over 5·3 L mmol⁻¹.
MATERIALS AND METHODS: Patients attending a hypertension unit between 2001 and 2006 and for who renin and aldosterone measurements and concomitant serum and urinary biochemistry data were available were included if diagnosed with PA (n = 449) or essential hypertension (n = 2209). We compared the diagnostic value of the SUSPPUP ratio and of serum potassium in the whole population, in patients without interfering drugs and in patients with lateralized PA.
RESULTS: The area under the ROC curve was significantly worse for the SUSPPUP ratio than for serum potassium in all groups: 0·72 vs. 0·76 in the whole population; 0·73 vs. 0·78 without interfering drugs; 0·76 vs. 0·82 for patients with lateralized PA. In the whole population, sensitivity was 71% for a SUSPPUP ratio ≥ 5·3 L mmol⁻¹ and serum potassium < 3·7 mmol L⁻¹, but specificity of the SUSPPUP ratio was significantly worse (61% vs. 69%). Using low serum potassium and/or high SUSPPUP ratio increased the sensitivity to 87% but decreased the specificity to 47%.
CONCLUSIONS: The SUSPPUP ratio was outperformed by serum potassium as a screening tool for PA in this large validation sample. Its value as an adjunct to serum potassium is questionable because of the low specificity of their combination.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955208     DOI: 10.1111/j.1365-2362.2010.02401.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

1.  Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Authors:  Bryan Williams; Thomas M MacDonald; Steve V Morant; David J Webb; Peter Sever; Gordon T McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Sandosh Padmanabhan; Isla S Mackenzie; Jackie Salsbury; Morris J Brown
Journal:  Lancet Diabetes Endocrinol       Date:  2018-04-11       Impact factor: 32.069

2.  Comparison of 24-h urinary aldosterone level and random urinary aldosterone-to-creatinine ratio in the diagnosis of primary aldosteronism.

Authors:  Che-Hsiung Wu; Ya-Wen Yang; Ya-Hui Hu; Yao-Chou Tsai; Ko-Lin Kuo; Yen-Hung Lin; Szu-Chun Hung; Vin-Cent Wu; Kwan-Dun Wu
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.